Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody

Blood

Volumn 121, Issue 14, 2013, Pages 2804-2813

  Yoshikawa, Mai ^a   Mukai, Yohei ^a,b   Okada, Yoshiaki ^a   Tsumori, Yuki ^a   Tsunoda, Shin Ichi ^b   Tsutsumi, Yasuo ^a,b   Aird, William C ^c   Yoshioka, Yasuo ^a   Okada, Naoki ^a   Doi, Takefumi ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; EARLY ENDOSOME ANTIGEN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; PROTEIN; ROUNDABOUT HOMOLOG 4 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ANTIBODY CONJUGATE; IMMUNOGLOBULIN RECEPTOR; NERVE PROTEIN; RECOMBINANT PROTEIN; ROBO4 PROTEIN, MOUSE; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY ISOLATION; ARTICLE; BODY WEIGHT; CELL ACTIVITY; CELL SURFACE; COMPARATIVE STUDY; CONFOCAL LASER SCANNING MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR GROWTH; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CELL LINE; DRUG DESIGN; HUMAN; IMMUNOLOGY; MELANOMA; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PEPTIDE LIBRARY; SKIN TUMOR; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BIOLOGICAL TRANSPORT; CELL LINE, TRANSFORMED; DRUG DESIGN; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOCONJUGATES; MELANOMA; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; PEPTIDE LIBRARY; RECEPTORS, IMMUNOLOGIC; RECOMBINANT PROTEINS; SKIN NEOPLASMS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MLCS; MLOWN;

EID: 84878263190     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-468363     Document Type: Article

References (51)

1. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14(4):529-537.
2. Isakoff SJ, Baselga J. Trastuzumab-DM1: Building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2- positive breast cancer. J Clin Oncol. 2011;29(4): 351-354.
3. Ansell SM. Brentuximab vedotin: Delivering an antimitotic drug to activated lymphoma cells. Expert Opin Investig Drugs. 2011;20(1):99-105.
4. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3(1):76-99.
5. Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: Current and future developments. MAbs. 2009; 1(3):247-253.
6. Poul MA, Becerril B, Nielsen UB, et al. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000;301(5): 1149-1161.
7. An F, Drummond DC, Wilson S, et al. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human singlechain antibodies. Mol Cancer Ther. 2008;7(3): 569-578.
8. Mukai Y, Sugita T, Yamato T, et al. Creation of novel Protein Transduction Domain (PTD) mutants by a phage display-based highthroughput screening system. Biol Pharm Bull. 2006;29(8):1570-1574.
9. Chaudhary VK, FitzGerald DJ, Adhya S, et al. Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc Natl Acad Sci USA. 1987;84(13):4538-4542.
10. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345(4): 241-247.
11. Pastan I, FitzGerald D. Pseudomonas exotoxin: Chimeric toxins. J Biol Chem. 1989;264(26): 15157-15160.
12. Legg JA, Herbert JMJ, Clissold P, et al. Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis. 2008; 11(1):13-21.
13. Huminiecki L, Bicknell R. In silico cloning of novel endothelial-specific genes. Genome Res. 2000; 10(11):1796-1806.
14. Huminiecki L, Gorn M, Suchting S, et al. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics. 2002;79(4):547-552.
15. Smith-Berdan S, Nguyen A, Hassanein D, et al. Robo4 cooperates with CXCR4 to specify hematopoietic stem cell localization to bone marrow niches. Cell Stem Cell. 2011;8(1):72-83.
16. Park KW, Morrison CM, Sorensen LK, et al. Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev Biol. 2003;261(1): 251-267.
17. Seth P, Lin Y, Hanai J, et al. Magic roundabout, a tumor endothelial marker: Expression and signaling. Biochem Biophys Res Commun. 2005; 332(2):533-541.
18. Okada Y, Yano K, Jin E, et al. A three-kilobase fragment of the human Robo4 promoter directs cell type-specific expression in endothelium. Circ Res. 2007;100(12):1712-1722.
19. Okada Y, Jin E, Nikolova-Krstevski V, et al. A GABP-binding element in the Robo4 promoter is necessary for endothelial expression in vivo. Blood. 2008;112(6):2336-2339.
20. Jones CA, London NR, Chen H, et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med. 2008;14(4):448-453.
21. Jones CA, Nishiya N, London NR, et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol. 2009; 11(11):1325-1331.
22. Marlow R, Binnewies M, Sorensen LK, et al. Vascular Robo4 restricts proangiogenic VEGF signaling in breast. Proc Natl Acad Sci USA. 2010;107(23):10520-10525.
23. Koch AW, Mathivet T, Larrivée B, et al. Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell. 2011;20(1):33-46.
24. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039-2049.
25. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002;4(Suppl 3):S81-S90.
26. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc. 2000;5(1):40-46.
27. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359-371.
28. Crawford Y, Ferrara N. VEGF inhibition: Insights from preclinical and clinical studies. Cell Tissue Res. 2009;335(1):261-269.
29. Wicki A, Rochlitz C, Orleth A, et al. Targeting tumor-associated endothelial cells: Anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res. 2012;18(2):454-464.
30. Witmer AN, Dai J, Weich HA, et al. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem. 2002;50(6):767-777.
31. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788-1795.
32. Eremina V, Jefferson JA, Kowalewska J, et al.VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129-1136
33. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011; 29(6):632-638.
34. Yoshikawa M, Mukai Y, Okada Y, et al. Ligandindependent assembly of purified soluble magic roundabout (Robo4), a tumor-specific endothelial marker. Protein Expr Purif. 2008;61(1):78-82.
35. Imai S, Mukai Y, Nagano K, et al. Quality enhancement of the non-immune phage scFv library to isolate effective antibodies. Biol Pharm Bull. 2006;29(7):1325-1330.
36. Yoshikawa M, Mukai Y, Tsunoda S, et al. Modifying the antigen-immunization schedule improves the variety of monoclonal antibodies obtained from immune-phage antibody libraries against HIV-1 Nef and Vif. J Biosci Bioeng. 2011; 111(5):597-599.
37. Yamamoto Y, Tsutsumi Y, Yoshioka Y, et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol. 2003;21(5):546-552.
38. Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962;194:495-496.
39. Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol. 1996;12:575-625.
40. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(9):1126-1136.
41. Pavlinkova G, Beresford GW, Booth BJ, et al. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J Nucl Med. 1999;40(9):1536-1546.
42. Schneider DW, Heitner T, Alicke B, et al. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J Nucl Med. 2009; 50(3):435-443.
43. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Deliv Rev. 2001;46(1-3): 169-185.
44. Kappen LS, Goldberg IH. Activation and inactivation of neocarzinostatin-induced cleavage of DNA. Nucleic Acids Res. 1978; 5(8):2959-2967.
45. Okamoto T, Mukai Y, Yoshioka Y, et al. Optimal construction of non-immune scFv phage display libraries from mouse bone marrow and spleen established to select specific scFvs efficiently binding to antigen. Biochem Biophys Res Commun. 2004;323(2): 583-591.
46. Silacci M, Brack S, Schirru G, et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics. 2005;5(9): 2340-2350.
47. Villa A, Lovato V, Bujak E, et al. A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin. MAbs. 2011; 3(3):264-272.
48. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002;62(24):7190-7194.
49. Pastan I, Hassan R, Fitzgerald DJ, et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6(7):559-565.
50. Chinnasamy D, Yu Z, Theoret MR, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest. 2010;120(11):3953-3968.
51. Nagayama H, Matsumoto K, Isoo N, et al. Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clin J Gastroenterol. 2010;3(6):307-317.